FFA
STRO icon

Farther Finance Advisors’s Sutro Biopharma STRO Stock Holding History

Farther Finance Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$17 – 4414
2024
Q4 		$17 Hold
1
– – ﹤0.01% 3942
2024
Q3 		$31 Buy
+1
New +$39 ﹤0.01% 3900

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Farther Finance Advisors's STRO Position: Q1 2025 in Review

Farther Finance Advisors sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 1 share — an estimated $17 sold.

Farther Finance Advisors first reported a position in STRO in Q3 2024 and held it in 2 quarters. The position peaked at $31 in Q3 2024. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Farther Finance Advisors reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 1 Sutro Biopharma share in Q1 2025, an estimated $17.
  • Farther Finance Advisors first reported a position in Sutro Biopharma in Q3 2024 and held it in 2 quarters.
  • Farther Finance Advisors's Sutro Biopharma position peaked at $31 in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Farther Finance Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.